Centene, Walgreens, RxAdvance form PBM model

Centene, Walgreens and RxAdvance have teamed up to form a pharmacy benefit management model to boost transparency and achieve better health outcomes with lower costs, the companies announced.

Centene is a managed care company with government-sponsored and private health plans, while RxAdvance is a full-service PBM based on the cloud. According to the announcement, the companies will deploy the model, which is targeted to serve the Medicaid population in particular. The model will reportedly provide higher quality care and lower pricing for drugs.

“Centene is committed to supporting a transparent pharmacy benefit management model that is sustainable with higher quality care for members at a lower cost to our customers,” Michael F. Neidorff, chairman, president and CEO of Centene, said in a statement. “This new approach to pharmacy management will improve the transparency and quality of care, while reducing unnecessary medical costs for millions of people.”

Walgreens also mentioned it made a “small investment” in RxAdvance. Centene also upped its stake in the PBM business after investing in March 2018.

“Collaboration between retail pharmacies and payers like Centene can further transform the way we provide care,” Stefano Pessina, executive vice chairman and CEO of Walgreens Boots Alliance, said in a statement. “Using RxAdvance’s Collaborative PBM Cloud, our partnership can empower our pharmacists to make critical decisions at the point of sale to help improve adherence and also to reduce avoidable medical costs.”

The collaboration comes at a time when the PBM industry has faced a handful of challenges over the past few years. PBMs have routinely been referred to as the middlemen of the drug market, negotiating rebates and other discounts between insurers and pharmaceutical companies. The Trump administration also recently proposed doing away with rebates altogether.

Walgreens’ rival CVS Health recently announced a new platform for its PBM clients.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.